Pharma Giants: Obesity Market Still Largely Untapped

Novo Nordisk's CEO, Mike Doustdar, has stated that the pharmaceutical sector is only "scratching the surface" of the enormous potential market for weight-loss drugs. He highlighted that in the US alone, approximately 110 million people are affected by obesity, yet current treatments, including those from Novo Nordisk, Eli Lilly, and compounding pharmacies, reach only 10 to 15 percent of this population.

In response to the need for expanded access, Novo Nordisk is implementing significant price cuts for its key medications. Starting in January, the wholesale prices for Wegovy and Ozempic in the US will decrease by 50% and 35%, respectively. This strategy aims to broaden the customer base by making these treatments more affordable, following similar agreements made with initiatives like the US president's prescription website.

Patent expiries present a major challenge for Novo Nordisk, particularly for semaglutide, the active ingredient in Ozempic and Wegovy. This active ingredient has already lost patent protection in Canada, India, Brazil, and China, leading to the launch of generic versions by numerous companies. Novo Nordisk's strategy to counter this includes price adjustments in price-sensitive markets like India, where Wegovy injections were reduced by up to 37% last year.

To maintain competitiveness against generics and expand its reach, Novo Nordisk emphasizes the quality and brand recognition of its products. The company also forms strategic partnerships, such as with Eurofarma in Brazil and Emcure Pharma in India, to launch Wegovy under local brands. Despite these efforts, a significant challenge remains the limited market size for weight-loss drugs in many global regions, with Novo Nordisk noting fewer patients are treated in India compared to Denmark.